Algiax Pharmaceuticals

Algiax Pharmaceuticals is a dynamic biotechnology company focused on the discovery and development of innovative pharmaceutical products, addressing critical unmet medical needs. With a strong emphasis on nervous system diseases, Algiax Pharmaceuticals is dedicated to advancing treatments for neuropathic pain and acute spinal cord injuries. The company's lead candidate, AP-325, is currently in clinical development for neuropathic pain treatment, while new chemical entities (AP-4 & AP-8) are in preclinical development for Diabetes Type 1 treatment.

Located at Max-Planck-Str. 15a, Erkrath, North Rhine-Westphalia 40699, DE, Algiax Pharmaceuticals employs a strategic approach, developing drug candidates up to Clinical Phase II-III. The company aims to out-license these advancements to pharmaceutical and biotech partners for further clinical development and market authorization, ensuring that innovative solutions reach patients in need.

Algiax Pharmaceuticals is committed to improving patient outcomes through cutting-edge research and development. We invite the management team to enhance this profile with a customized company showcase and product listing on our platform, providing greater visibility and engagement opportunities. We believe this will significantly contribute to the company’s continued growth and success.